Novo Nordisk Beats Expectations as Wegovy Sales Lift Q3 Results

Direct answer

Novo Nordisk, the Danish maker of Wegovy and Ozempic, reported stronger than expected results for the third quarter of 2026 and raised its full-year outlook. Reuters reported on November 4 that adjusted operating profit rose 27 percent at constant exchange rates to 31,720 million Danish kroner, beating forecasts, as weight loss drug sales kept growing.

What happened

Novo Nordisk said in its November 4 report for the first nine months of 2026 that adjusted sales in the third quarter reached 79,195 million Danish kroner, up 4 percent at constant exchange rates. That was above the around 73.6 billion kroner analysts had expected.

Sales of the Wegovy tablet reached almost 5.4 billion kroner in the quarter, above expectations of 4.6 billion kroner, while Ozempic sales were also better than expected. The company raised its full-year outlook for both adjusted sales and adjusted operating profit to a range of minus 2 percent to plus 2 percent at constant exchange rates, up from the earlier range of minus 6 percent to zero percent.

Reported operating profit fell 9 percent at constant exchange rates, because the quarter included 8.7 billion kroner of non-cash impairment charges, including 4.6 billion kroner linked to ziltivekimab and 4.1 billion kroner from resizing its manufacturing network. Adjusted profit strips out those one-off items, which is why the adjusted figure rose while the reported figure fell.

Why it matters for beginners

Novo Nordisk is a good example of how one product line can drive a whole company. Its GLP-1 medicines, used for diabetes and weight management, are its main growth engine. When sales of those medicines beat expectations, the whole outlook improves, even if the company also records large one-off charges in the same quarter.

For beginners, the key lesson is to look past a single headline number. Adjusted profit and reported profit can move in opposite directions when one-off charges are involved. The outlook change also matters, because it tells investors what management now expects for the full year, not just what happened in one quarter.

This story is similar to other drug company results this earnings season, such as Teva, which also beat expectations on branded drug sales. Teva Beats Profit Expectations in Q3 as Branded Drug Sales Jump

What to watch next

Watch whether Wegovy pill sales keep growing in the fourth quarter, and whether the company holds its raised outlook when it reports full-year results. Also watch competition from Eli Lilly in the weight loss market, and any update on the planned early 2027 launch of CagriSema in the United States, which is still subject to approval. Novo Nordisk is due to hold an earnings call on November 4, which may add detail on demand and pricing.

FAQ

What is Novo Nordisk?

Novo Nordisk is a Danish pharmaceutical company best known for its diabetes and weight management medicines, including Ozempic and Wegovy, which both use the active ingredient semaglutide.

Why did Novo Nordisk raise its outlook?

It raised its outlook because third quarter sales and adjusted profit beat expectations, driven mainly by continued growth in its GLP-1 medicines, especially in obesity treatment.

What is the difference between adjusted and reported profit?

Reported profit includes all charges, including one-off impairments. Adjusted profit removes items the company calls exceptional, so it can show the underlying trading trend more clearly. In this quarter, adjusted profit rose 27 percent at constant exchange rates while reported profit fell 9 percent, mainly because of 8.7 billion kroner of impairment charges.

Does this mean the shares will rise?

Not necessarily. Share prices react to many things, including the wider market, competition, and what investors had already expected. A beat can still be followed by a fall if investors focus on a different detail, such as future guidance or competition.